clinical trial · NCT07105059

A Study of Teclistamab and Mezigdomide in People With Multiple Myeloma

Memorial Sloan Kettering Cancer Center →·phase1·recruiting·n = 18

Multiple MyelomaTeclistamabMezigdomide

brief summary

The researchers are doing this study to find out whether combining teclistamab and mezigdomide is a safe and effective treatment approach in people with relapsed/refractory multiple myeloma (MM).

started

Aug 8, 2025

primary completion

Aug 8, 2028

completion

Aug 8, 2028

last updated

Feb 9, 2026

official title

Teclistamab and Mezigdomide for Relapsed/Refractory Multiple Myeloma

full record on clinicaltrials.gov ↗

sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol